US listing, what happens then?, page-5

I doubt very much that we'll have a dual listing and I doubt very much that you actually mean a dual listing. I think you're confusing a dual listing with a cross listing (I.e. ADR or CDI). A dual listing would be far to expensive for now, and most companies that are dual listed did so before ADR's and CDI's come into existence (e.g. BHP, RIO, etc). The experience you are talking about personally having is a cross listing via CDI's. Personally I understand your comments about volatility and shorting when the company has a primary listing in the US, but it's a little simplistic to apply the experience of one company (and an early stage medical device company where the risk profile is very different and the number of hurdles to clover are bigger and less well defined) to evey other company that has a cross listing.